Oligo Synthesis : CEPs
Prices quoted are for single packs only. For multiples of the same product please request a quote. Some of Glen"sproductsarehazardousandmay be subject to additional shipping charges. Full product information is available onGlen Research"s website.
Amino-Modifier C2 dT
Amino-Modifier C2 dT
Glen Research
| Catalogue No. | Description | Pack Size | Price | Qty |
|
|---|---|---|---|---|---|
| 10-1037-02 | Amino-Modifier C2 dT | 0.25g | £288.00£273.60Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
| 10-1037-05 | Amino-Modifier C2 dT | 0.5g | £576.00£547.20Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
| 10-1037-90 | Amino-Modifier C2 dT | 100µmoles | £144.00£136.80Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
Related products
Amino-Modifier C2 dT
Amino-Modifier C2 dT
Glen Research
| Amino-Modifier C2 dT |
Catalog Number: 10-1037-xx
Description: Amino-Modifier C2 dT
| 5"-Dimethoxytrityl-5-[N-(trifluoroacetylaminoethyl)-3-acrylimido]-2"-deoxyUridine,3"-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite | ||
| Formula: C46H54N6O10F3P | M.W.: 938.94 | F.W.: 402.30 |
Diluent: Anhydrous Acetonitrile |
| Coupling: Amino-Modifier C2 dT reacts in a manner identical to normal phosphoramidites.To prevent side reactions, synthesize using acetyl-protected dC. See Deprotection for further details. |
| Deprotection:No changes needed from standard method recommended by synthesizer manufacturer. The TFA protecting group is removed during standard ammonium hydroxide deprotection.A minor side reaction during ammonia deprotection can lead to irreversibly capping 2-5% of the amine. This could be significant if multiple additions of the modifier are made. To prevent the reaction, synthesize using acetyl-protected dC and deprotect in 30% ammonia/40% methylamine 1:1 (AMA) at 65°C for 15 minutes. |
| Storage: Refrigerated storage, maximum of 2-8°C, dry |
Stability in Solution: 24 hours SEQUENCE MODIFIERSSequence Modifiers are designed for use in automated synthesis.The carboxy-dT is hydrolyzed during deprotection and can be coupled directly toa molecule containing a primary amino group by a standard peptide coupling orvia the intermediate N-hydroxysuccinimide (NHS) ester. Amino-Modifier dA,Amino-Modifier dC, Amino-Modifier dG and both Amino-Modifier dT products can beadded in place of a dA, dC, dG and dT residue, respectively, duringoligonucleotide synthesis. Corresponding Amino-Modifier supports can replacetheir respective deoxynucleoside supports. After deprotection, the primary amineon the C6 analogues is separated from the oligonucleotide by a spacer arm with atotal of 7 -10 atoms and can be labelled or attached to an enzyme. The C2analogue is more suitable for the attachment of molecules designed to react withthe oligonucleotide. |
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
Amino-Modifier C2 dT
Amino-Modifier C2 dT
Glen Research
MSDS
Glen Report 6.1: DEOXYURIDINE DERIVATIVES FOR INTERNAL MODIFICATION
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
Amino-Modifier C2 dT
Amino-Modifier C2 dT
Glen Research
(1) J.L. Ruth, C. Morgan, and A. Pasko, DNA, 1985, 4, 93.(2) J. Telser, K.A. Cruickshank, L.E. Morrison, and T.L. Netzel, J. Am. Chem. Soc., 1989, 111, 6966-6976.(3) E. Jablonski, E.W. Moomaw, R.H. Tullis, and J.L. Ruth, Nucleic Acids Res., 1986, 14, 6115.(4) J.G. Farmar and M. Castaneda, Biotechniques, 1991, 11, 588-589.
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
Amino-Modifier C2 dT
Amino-Modifier C2 dT
Glen Research
Amino-Modifier C2 dT
| 5"-Dimethoxytrityl-5-[N-(trifluoroacetylaminoethyl)-3-acrylimido]-2"-deoxyUridine,3"-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite | ||
| Formula: C46H54N6O10F3P | M.W.: 938.94 | F.W.: 402.30 |
Diluent: Anhydrous Acetonitrile |
| Coupling: Amino-Modifier C2 dT reacts in a manner identical to normal phosphoramidites. To prevent side reactions, synthesize using acetyl-protected dC. See Deprotection for futher details. |
| Deprotection: No changes needed from standard method recommended by synthesizer manufacturer. The TFA protecting group is removed during standard ammonium hydroxide deprotection. A minor side reaction during ammonia deprotection can lead to irreversibly capping 2-5% of the amine. This could be significant if multiple additions of the modifier are made. To prevent the reaction, synthesize using acetyl-protected dC and deprotect in 30% ammonia/40% methylamine 1:1 (AMA) at 65°C for 15 minutes. |
| Storage: Refrigerated storage, maximum of 2-8°C, dry |
| Stability in Solution: 24 hours |
| Does not affect hybridization |
| Material Safety Data Sheet |
Literature Highlights
| Glen Report 6.1: DEOXYURIDINE DERIVATIVES FOR INTERNAL MODIFICATION |
Frequently Asked Technical Question
QUESTION: What is the extinction coefficient of Amino-Modifier C6 dT and C2 dT?
RESPONSE:The extinction coefficient of DNA at 260nm is around 10,000/mole or 10/µmole. The extiction coefficient of Amino-Modifier C6 dT and C2 dT is around 8.7. The synthesis of these monomers does not pass through the deoxynucleoside and this figure is estimated by comparison to dT-CE Phosphoramidite.
Note: dA=15.4, dC=7.4, dG=11.5, T=8.7
DILUTION/COUPLING DATA
The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures. Please link for more detailed usage information with the various synthesizers.
| ABI 392/394 | |||||||||
| Cat.No. | PackSize | Grams/Pack | 0.1M Dil.(mL) | LV40 | LV200 | 40nm | 0.2µm | 1µm | 10µm |
| Approximate Number of Additions | |||||||||
| 10-1037-02 | 0.25grams | .25grams | 2.66 | 75.33 | 45.2 | 28.25 | 20.55 | 15.07 | 3.77 |
| 10-1037-05 | 0.5grams | .5grams | 5.33 | 164.33 | 98.6 | 61.63 | 44.82 | 32.87 | 8.22 |
| 10-1037-90 | 100µmoles | .094grams | 1 | 20 | 12 | 7.5 | 5.45 | 4 | 1 |
| Expedite | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 50nm | 0.2µm | 1µm | 15µm | |
| Approximate Number of Additions | |||||||||
| 10-1037-02 | 0.25grams | .25grams | 3.97 | .067 | 73 | 45.63 | 33.18 | 4.56 | |
| 10-1037-05 | 0.5grams | .5grams | 7.95 | .067 | 152.6 | 95.38 | 69.36 | 9.54 | |
| 10-1037-90 | 100µmoles | .094grams | 1.5 | .067 | 23.6 | 14.75 | 10.73 | 1.48 | |
| Beckman | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 30nm | 200nm | 1000nm | ||
| Approximate Number of Additions | |||||||||
| 10-1037-02 | 0.25grams | .25grams | 3.97 | .067 | 74.6 | 46.63 | 33.91 | ||
| 10-1037-05 | 0.5grams | .5grams | 7.95 | .067 | 154.2 | 96.38 | 70.09 | ||
| 10-1037-90 | 100µmoles | .094grams | 1.5 | .067 | 25.2 | 15.75 | 11.45 | ||
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
Amino-Modifier C2 dT
Amino-Modifier C2 dT
Glen Research
Frequently Asked Technical Question
QUESTION: What is the extinction coefficient of Amino-Modifier C6 dT and C2 dT?
RESPONSE:The extinction coefficient of DNA at 260nm is around 10,000/mole or 10/µmole.The extiction coefficient of Amino-Modifier C6 dT and C2 dT is around 8.7.The synthesis of these monomers does not pass through the deoxynucleoside and this figure is estimated by comparison to dT-CE Phosphoramidite.
Note:dA=15.4, dC=7.4, dG=11.5, T=8.7
DILUTION/COUPLING DATA
The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures. Please link for more detailed usage information with the various synthesizers.
| ABI 392/394 | |||||||||
| Cat.No. | PackSize | Grams/Pack | 0.1M Dil.(mL) | LV40 | LV200 | 40nm | 0.2µm | 1µm | 10µm |
| Approximate Number of Additions | |||||||||
| 10-1037-02 | 0.25grams | .25grams | 2.66 | 75.33 | 45.2 | 28.25 | 20.55 | 15.07 | 3.77 |
| 10-1037-05 | 0.5grams | .5grams | 5.33 | 164.33 | 98.6 | 61.63 | 44.82 | 32.87 | 8.22 |
| 10-1037-90 | 100µmoles | .094grams | 1 | 20 | 12 | 7.5 | 5.45 | 4 | 1 |
| Expedite | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 50nm | 0.2µm | 1µm | 15µm | |
| Approximate Number of Additions | |||||||||
| 10-1037-02 | 0.25grams | .25grams | 3.97 | .07 | 73 | 45.63 | 33.18 | 4.56 | |
| 10-1037-05 | 0.5grams | .5grams | 7.95 | .07 | 152.6 | 95.38 | 69.36 | 9.54 | |
| 10-1037-90 | 100µmoles | .094grams | 1.5 | .07 | 23.6 | 14.75 | 10.73 | 1.48 | |
| Beckman | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 30nm | 200nm | 1000nm | ||
| Approximate Number of Additions | |||||||||
| 10-1037-02 | 0.25grams | .25grams | 3.97 | .07 | 74.6 | 46.63 | 33.91 | ||
| 10-1037-05 | 0.5grams | .5grams | 7.95 | .07 | 154.2 | 96.38 | 70.09 | ||
| 10-1037-90 | 100µmoles | .094grams | 1.5 | .07 | 25.2 | 15.75 | 11.45 | ||
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
多种天然提取的人类蛋白质产品；多种兔抗人类蛋白质抗血清。
| Albumin, Human Plasma | 16-16-011202 |
|
|
16-16-010700 |
| Alpha 1 Antichymotrypsin, Human Plasma | 16-16-012400 |
| Alpha 1 Antitrypsin, Human Plasma | 16-16-011609 |
| Alpha 2 Antiplasmin, Human Plasma | 16-16-012901 |
| Alpha 2 HS Glycoprotein, Human Plasma | 16-16-081907 |
| Alpha 2 Macroglobulin, Human Plasma | 16-16-012013 |
| Angiotensinogen, Human Plasma | 16-16-011407 |
| Antisera to Albumin, Human Plasma | 01-16-011202 |
| Antisera to Amylase, Human Pancreas | 01-19-010000 |
| Antisera to Apolipoprotein AI, Human Plasma | 01-16-120101 |
| Antisera to Apolipoprotein CII, Human Plasma | 01-16-120302 |
| Antisera to Azurocidin, Human Neutrophil | 01-14-012621 |
| Antisera to Catalase, Human Erythrocyte | 01-05-030000 |
| Antisera to Cathepsin B, Human Liver | 01-12-030102 |
| Antisera to Cathepsin D, Human Liver | 01-12-030104 |
| Antisera to Cathepsin H, Human Liver | 01-12-030108 |
| Antisera to Cathepsin L, Human Liver | 01-12-030112 |
| Antisera to Elastase, Human Neutrophil | 01-14-051200 |
| Antisera to Fibrinogen, Human Plasma | 01-16-060902 |
| Antisera to Kallikrein, Human Plasma | 01-16-110112 |
| Antisera to Myeloperoxidase, Human Neutrophil | 01-14-130000 |
| Antisera to Thrombospondin, Human Platelet | 01-20-201319 |
| Antisera to Trypsin, Human Pancreas | 01-19-032000 |
| Antithrombin III, Human Plasma | 16-16-012020 |
| Apolipoprotein AI, Human Plasma | 16-16-120101 |
| Apolipoprotein AII, Human Plasma | 16-16-120102 |
| Apolipoprotein AIV, Human Plasma | 16-16-120104 |
| Apolipoprotein B, Human Plasma | 16-16-120200 |
| Apolipoprotein CI, Human Plasma | 16-16-120301 |
| Apolipoprotein CII, Human Plasma | 16-16-120302 |
| Apolipoprotein CIII, Human Plasma | 16-16-120303 |
| Apolipoprotein E, Human Plasma | 16-16-120500 |
| Apotransferrin, Dog Plasma | 16-16-A32001-dog |
| Apotransferrin, Human Plasma | 16-16-A32001 |
| Apotransferrin, Human Plasma, Low Endotoxin Level | 16-16-A32001-LEL |
| Apotransferrin, Mouse Plasma | 16-16-A32001-mouse |
| Apotransferrin, Rat Serum | 16-16-A32001-rat |
| Azurocidin, Human Neutrophil (Cationic protein 37) | 16-14-012621 |
| Bacterial/Permeability-Increasing Protein, Human Neutrophil (BPI, CAP57) | 16-14-021609 |
| C1 Esterase Inhibitor, Human Plasma | 16-16-031509 |
| Calmodulin, Bovine Brain, High Purity | 16-BR-030112-HP-bovine |
| Calpain-1, Human Erythrocyte | 16-05-030112 |
| Calpain-1, Porcine Erythrocytes | 16-05-030112-P |
| Catalase, Human Erythrocyte | 16-05-030000 |
| Cathepsin B, Bovine Spleen | 16-SP-030102-bovine |
| Cathepsin B, Human Liver | 16-12-030102 |
| Cathepsin D, Bovine Spleen | 16-SP-030104-bovine |
| Cathepsin D, Human Liver | 16-12-030104 |
| Cathepsin G, Human Neutrophil | 16-14-030107 |
| Cathepsin H, Human Liver | 16-12-030108 |
| Cathepsin L, Human Liver | 16-12-030112 |
| Cathepsin S, Human Spleen | 16-18-030118 |
| Ceruloplasmin, Human Plasma | 16-16-030518 |
| Chylomicrons, Human Plasma | 12-16-030825 |
| Chymotrypsin, Human Pancreas | 16-19-030820 |
| Defensins, Alpha, Mixed from Human Neutrophils (HNP) | 16-14-081416 |
| Dipeptidyl Peptidase IV, Human Placenta | 16-23-041606 |
| Elastase, Human Neutrophil | 16-14-051200 |
| Eosinophil Cationic Protein, Human Eosinophils (ECP) | 16-15-050316 |
| Eosinophil Derived Neurotoxin, Human Eosinophils (EDN) | 16-15-050414 |
| Eosinophil Peroxidase, Human Eosinophils (EPO) | 16-15-160518 |
| Factor Va, Human Plasma | 16-16-060601 |
| GC-Globulin, Human Plasma, Mixed Type (维D结合蛋白) | 16-16-070307 |
| Haptoglobin, Human Plasma, Mixed Type | 16-16-080116 |
| Hemopexin, Human Plasma | 16-16-080513 |
| Immunoglobulin A, Human Plasma | 16-16-090701 |
| Immunoglobulin A1, Human Myeloma Protein | 16-16-090701-1M |
| Immunoglobulin A2, Human Myeloma Plasma | 16-16-090701-2M |
| Immunoglobulin D, Human Myeloma Plasma | 16-16-090704-M |
| Immunoglobulin D, Human Plasma | 16-16-090704 |
| Immunoglobulin E, Human Myeloma Plasma | 16-16-090705-M |
| Immunoglobulin E, Human Plasma | 16-16-090705 |
| Immunoglobulin G, Dog Plasma | 16-16-090707-dog |
| Immunoglobulin G, Human Plasma | 16-16-090707 |
| Immunoglobulin G, Human Plasma, Fab Fragment | 16-16-090707-Fab |
| Immunoglobulin G, Human Plasma, FC Fragment | 16-16-090707-FC |
| Immunoglobulin G, Mouse Plasma | 16-16-090707-mouse |
| Immunoglobulin G, Rat Serum | 16-16-090707-rat |
| Immunoglobulin G1, Human Myeloma Plasma | 16-16-090707-1M |
| Immunoglobulin G2, Human Myeloma Plasma | 16-16-090707-2M |
| Immunoglobulin G3, Human Plasma | 16-16-090707-3 |
| Immunoglobulin G4, Human Myeloma Plasma | 16-16-090707-4M |
| Immunoglobulin M, Fc5mu, Human Plasma | 16-16-090713-Mfc5u |
| Immunoglobulin M, Human Myeloma Plasma | 16-16-090713-M |
| Immunoglobulin M, Human Plasma | 16-16-090713 |
| Immunoglobulin M, mu Chain, Human Plasma | 16-16-090713-MU |
| Kallikrein, Human Plasma | 16-16-110112 |
| Kininogen, HMW, Human Plasma | 16-16-110914-H |
| Kininogen, LMW, Human Plasma | 16-16-110914-L |
| Lactalbumin, Human Milk | 13-16-011202 |
| Lactoferrin, Human Neutrophil | 16-14-120103 |
| Lipoprotein a, [Lp(a)], Human Plasma | 12-16-121601 |
| Lipoproteins, High Density, Human Plasma | 12-16-080412 |
| Lipoproteins, High Density, Human Plasma, 适于细胞培养 | 12-16-080412-TC |
| Lipoproteins, Intermediate Density, Human Plasma | 12-16-090412 |
| Lipoproteins, Low Density, Human Plasma | 12-16-120412 |
| Lipoproteins, Low Density, Human Plasma, 适于细胞培养 | 12-16-120412-TC |
| Lipoproteins, Very Low Density, Human Plasma | 12-16-221204 |
| Lipoproteins, Very Low Density, Human Plasma, 适于细胞培养 | 12-16-221204-TC |
| Lysozyme, Human Neutrophil | 16-14-122519 |
| Myeloperoxidase, Human Neutrophil | 16-14-130000 |
| Plasmin, Human Plasma, Frozen | 16-16-161213-F |
| Plasmin, Human Plasma, Lyophilized | 16-16-161213-L |
| Plasminogen, Human Plasma | 16-16-161200 |
| Platelet Factor 4, Human Platelet | 16-20-060306 |
| Prealbumin, Human Plasma (Transthyretin) | 16-16-161801 |
| Proteinase 3, Human Neutrophil | 16-14-161820 |
| S-100 Protein, Bovine Brain | 16-BR-190816-bovine |
| S-100b Protein, Bovine Brain | 16-BR-190802-bovine |
| S-100αα Protein, Bovine Brain | 16-BR-190801-bovine |
| Serum Amyloid A, Human Plasma | 16-16-190101 |
| Thrombospondin, Human Platelet | 16-20-201319 |
| Transferrin, Dog Plasma | 16-16-032001-dog |
| Transferrin, Human Plasma | 16-16-032001 |
| Transferrin, Human Plasma, 组织培养级 | 16-16-032001-LEL |
| Transferrin, Mouse Plasma | 16-16-032001-mouse |
| Transferrin, Rat Serum | 16-16-032001-rat |
| Trypsin, Human Pancreas | 16-19-032000 |
| Vitronectin, Human Plasma | 16-16-220920 |
本网站将在规定时间内给予删除等相关处理。
